aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. CCH:LN
5. META
6. CCHGY
7. PRY:IM
8. PRYMY
9. SKA-B
10. PBA

Go back to aTyr Pharma Announces First Quarter 2020 Results and Provides Corporate Update on ATYR1923 Clinical Trials in Pulmonary Sarcoidosis and COVID-19

aTyr Pharma (LIFE) Tops Q1 EPS by 43c, Revenues Beat

May 12, 2020 4:22 PM EDT

aTyr Pharma (NASDAQ: LIFE) reported Q1 EPS of $0.25, $0.43 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $4.4 million.

As the COVID-19 pandemic continues to unfold, we are abiding by government directives to keep our patients, investigators, site personnel and employees safe. While some of our investigational sites for our ongoing trial of ATYR1923... More